PMV Pharmaceuticals, Inc.

NasdaqGS:PMVP Rapport sur les actions

Capitalisation boursière : US$82.4m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

PMV Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Le PDG PMV Pharmaceuticals' est David Mack, nommé en Jul2013, a un mandat de 11.08 ans. La rémunération annuelle totale est $ 2.21M, composée du salaire de 26.5% et des bonus 73.5%, y compris les actions et options de la société. détient directement 1.26% des actions de la société, d'une valeur de $ 1.04M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.5 ans et 3.5 ans.

Informations clés

David Mack

Directeur général

US$2.2m

Rémunération totale

Pourcentage du salaire du PDG26.5%
Durée du mandat du directeur général11.1yrs
Propriété du PDG1.3%
Durée moyenne d'occupation des postes de direction3.5yrs
Durée moyenne du mandat des membres du conseil d'administration3.5yrs

Mises à jour récentes de la gestion

Recent updates

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

Aug 04
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Apr 20
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Dec 22
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Sep 08
We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

May 10
Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Jan 11
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Sep 22
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

Aug 09

PMV Pharma joins Merck to study lead candidate with Keytruda

Jul 18

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Jun 09
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Feb 23
Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Nov 05
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Jul 23
Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

Apr 09
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

Dec 25
Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

PMV Pharmaceuticals reports Q3 results

Nov 13

Analyse de la rémunération des PDG

Comment la rémunération de David Mack a-t-elle évolué par rapport aux bénéfices de PMV Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$49m

Mar 31 2024n/an/a

-US$65m

Dec 31 2023US$2mUS$586k

-US$69m

Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$74m

Dec 31 2022US$4mUS$564k

-US$73m

Sep 30 2022n/an/a

-US$72m

Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$65m

Dec 31 2021US$4mUS$545k

-US$58m

Sep 30 2021n/an/a

-US$50m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020US$1mUS$495k

-US$34m

Sep 30 2020n/an/a

-US$31m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$27m

Dec 31 2019US$628kUS$461k

-US$25m

Rémunération vs marché: La rémunération totale de David ($USD 2.21M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de David a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

David Mack (62 yo)

11.1yrs

Titularisation

US$2,209,795

Compensation

Dr. David H. Mack, Ph D., Co-founded PMV Pharmaceuticals, Inc. in 2013 and also serves as its President and Chief Executive Officer since July 2013. Dr. Mack joined the PMV Pharmaceuticals, Inc. in 2013.D...


Équipe de direction

NomPositionTitularisationCompensationPropriété
David Mack
Co-Founder11.1yrsUS$2.21m1.26%
$ 1.0m
Arnold Levine
Co-Founder11.6yrsUS$220.27k0.80%
$ 655.7k
Deepika Jalota
Chief Development Officer5.2yrsUS$1.10m0.058%
$ 47.9k
Michael Carulli
Chief Financial Officerless than a yearpas de donnéespas de données
Robert Ticktin
General Counsel4yrspas de donnéespas de données
Tim Smith
Senior VP and Head of Corporate Development & Investor Relations2.9yrspas de donnéespas de données
Crystal Zuckerman
Vice President of Human Resources1.6yrspas de donnéespas de données
Binh Vu
Senior Vice President of Drug Discovery & CMCno datapas de donnéespas de données
Marc Fellous
Senior VP and Head of Clinical Development & Medical Affairs1.3yrspas de donnéespas de données
Laura De Leon
VP & Head of Clinical Operationsno datapas de donnéespas de données

3.5yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Gestion expérimentée: L'équipe de direction de PMVP est considérée comme expérimentée (ancienneté moyenne 3.5 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
David Mack
Co-Founder11.2yrsUS$2.21m1.26%
$ 1.0m
Arnold Levine
Co-Founder11.2yrsUS$220.27k0.80%
$ 655.7k
Charles Sawyers
Member of Clinical Advisory Boardno datapas de donnéespas de données
Carol Gallagher
Independent Director1.8yrsUS$124.27kpas de données
Richard Heyman
Independent Chairman of the Board of Directors & Member of Scientific Advisory Board4.2yrsUS$176.77k0%
$ 0
Scott Lowe
Chairman of Scientific Advisory Boardless than a yearpas de donnéespas de données
Charles Baum
Independent Director & Chair of Clinical Advisory Board3.3yrsUS$133.27k0%
$ 0
Laurie Stelzer
Independent Director4yrsUS$140.27k0%
$ 0
Kirsten Flowers
Independent Director2.6yrsUS$127.77k0%
$ 0
Guillermina Lozano
Member of Scientific Advisory Board3.5yrspas de donnéespas de données

3.5yrs

Durée moyenne de l'emploi

63.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de PMVP sont considérés comme expérimentés (ancienneté moyenne 3.5 ans).